Cerebrotendinous xanthomatosis: 11-Year treatment with chenodeoxycholic acid in five patients. An electrophysiological study

Journal of the Neurological Sciences

Volumn 190, Issue 1-2, 2001, Pages 29-33

  Mondelli, Mauro ^a   Sicurelli, Francesco ^b   Scarpini, Chiara ^b   Dotti, Maria Teresa ^b   Federico, Antonio ^b  

^a Serv EMG ASL 7   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Cerebrotendinous xanthomatosis; Chenodeoxycholic acid; Evoked potentials; Nerve conduction velocities

Indexed keywords

CHENODEOXYCHOLIC ACID; CHOLESTANOL; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; BLOOD; CEREBROTENDINOUS XANTHOMATOSIS; CLINICAL TRIAL; DRUG EFFECT; EVOKED BRAIN STEM AUDITORY RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MALE; NERVE CONDUCTION; NERVOUS SYSTEM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REACTION TIME; TREATMENT OUTCOME;

ADULT; CHENODEOXYCHOLIC ACID; CHOLESTANOL; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; EVOKED POTENTIALS, SOMATOSENSORY; EVOKED POTENTIALS, VISUAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; NERVOUS SYSTEM; NEURAL CONDUCTION; REACTION TIME; TREATMENT OUTCOME; XANTHOMATOSIS, CEREBROTENDINOUS;

EID: 0035885804     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(01)00563-9     Document Type: Article

References (27)

1. Federico A, Dotti MT. Cerebrotendinous xanthomatosis. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: Elsevier 1996:599-613.
2. Vemps A, Hoefsloot LH, Steenbergen GCH, Theelen JP, Wevers RA, Gabreëls JM, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000; 123:908-19.
3. Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 1984;311:1649-52.
4. Mondelli M, Rossi A, Scarpini C, Dotti MT, Federico A. Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid. Arch Neurol 1992;49:469-75.
5. Garuti R, Croce MA, Tiozzo R, Dotti MT, Federico A, Bertolini S, et al. Four novel mutations of sterol 27-hydroxylase gene in Italian patients with cerebrotendinous xanthomatosis. J Lipid Res 1997; 38:2322-34.
6. Restuccia D, Di Lazzaro V, Servidei S, Colosimo C, Tonali P. Somatosensory and motor evoked potentials in the assessment of cerebrotendinous xanthomathosis before and after treatment with chenodeoxycholic acid: a preliminary study. J Neurol Sci 1992; 112:139-46.
7. Salen G, Meriwether TW, Nicolau G. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med 1975;14:57-74.
8. Donaghy M, King RHM, McKeran RO, Schwartz MS, Thomas PK. Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid. J Neurol 1990;237:216-9.
9. Pedley TA, Emerson RG, Warner CL, Rowland L, Salen G. Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. Ann Neurol 1985;18:517-8.
10. Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis HJGH. Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in the Netherlands. Clin Neurol Neurosurg 1987;89:169-75.
11. Nakamura T, Matsuzawa Y, Takemura K, Kubo M, Miki H, Tarui S. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma levels associated with marked regression of tendon xanthomas in CTX. Metabolism 1991;40:741-6.
12. Kuriyama M, Tokimura Y, Fujiyama J, Utatsu Y, Osame M. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci 1994;125: 22-8.
13. Thompson PD, Day BL, Rothwell JC. The interpretation of electromyographic responses to electrical stimulation of the motor cortex in diseases of the upper motor neurone. J Neurol Sci 1987;80:91-110.
14. Mills KR, Murray NMF, Hess CW. Magnetic and electrical transcranial brain stimulation: physiological mechanisms and clinical applications. Neurosurgery 1987;20:164-8.
15. Rossini PM, Caramia MD. Methodological and physiological considerations on electric or magnetic transcranial stimulation. In: Rossini PM, Marsden CD, editors. Noninvasive stimulation of brain and spinal cord: fundamentals and clinical applications. New York, NY: Alan R. Liss 1988:1-28.
16. Brown P. Pathophysiology of spasticity. J Neurol, Neurosurg, Psychiatry 1994;57:773-7.
17. Tokimura Y, Kuriyama M, Arimura K, Fujiyama J, Osame M. Electrophysiological study in cerebrotendinous xanthomathosis. J Neurol, Neurosurg, Psychiatry 1992;55:52-5.
18. Berginer VM, Berginer J, Korczyn AD, Tadmor R. Magnetic resonance imaging in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study. J Neurol Sci 1994;122:102-8.
19. Pop PHM, Joosten E, van Spreeken A, Gagreëls-Felsten A, Jaspar H, ter Laak H, et al. Neuroaxonal pathology of central and peripheral nervous systems in cerebrotendinous xanthomatosis (CTX). Acta Neurophatol 1984;64:259-64.
20. Soffer D, Benharroch D, Berginer V. The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol 1995;90:213-20.
21. Dotti MT, Federico A, Signorini E, Caputo N, Venturi C, Filosomi G, et al. Cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease): CT and MR findings. AJNR 1994;15:1721-6.
22. De Stefano N, Dotti MT, Mortilla M, Dal Pozzo GC, Federico A. Magnetic resonance imaging and spectroscopic changes in brain of patients with cerebrotendinous xanthomatosis. Brain 2001;124:121-31.
23. van Heijst AFJ, Verrips A, Wevers RA, Cruysberg JRM, Renier WO, Tolboom JJM. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 1998;157:313-6.
24. Peynet J, Laurent A, DeLiege P, Lecoz P, Gambert P, Legrand A, et al. Cerebrotendinous xanthomatosis: treatment with simvastatin, lovastatin and chenodeoxycholic acid in 3 siblings. Neurology 1991; 41:434-6.
25. Verrips A, Wevers RA, Van Engelen BGM, Keyser A, Wolthers BG, Barkhof F, et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 1999;48:233-8.
26. Federico A, Dotti MT. Treatment of cerebrotendinous xanthomatosis. Neurology 1994;44:2218.
27. Federico A, Dotti MT, Volpi N. Muscle mitochondrial changes in cerebrotendinous xanthomatosis. Ann Neurol 1991;30:734-5.